FGF3 Amplification

CI-VAR-00000222Explore in graph →CIViC 630

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Hepatocellular Carcinoma1
FGF3 Amplification	Sorafenib	Predictive	C	Supports Sensitivity Response	3	submitted	EID1966 FGF3/FGF4 amplification was observed in around 2% of HCCs. Although the sample size was relatively small, FGF3/FGF4 amplification, a poorly differentiated histological type, and multiple lung metastas… (full text at CIViC) PMID 22890726 · Arao et al., 2013 · Open in CIViC	civic
Malignant Breast Neoplasm1
FGF3 Amplification	Dovitinib	Predictive	B	Supports Sensitivity Response	2	accepted	EID1606 81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, resp… (full text at CIViC) PMID 23658459 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm1
FGF3 Amplification	Sorafenib	Predictive	D	Supports Sensitivity Response	2	submitted	EID13274 Among 26 cancer cell lines tested for growth inhibition by sorafenib, KYSE220 was the only FGF3/FGF4-amplified cell line and showed marked sorafenib sensitivity, with an IC50 of 0.18 μM. PMID 22890726 · Arao et al., 2013 · Open in CIViC	civic